
Dual-Target CD19/CD20 CAR T-Cell Therapy Achieves 63.6% Complete Remission Rate in R/R B-NHL
A dual-target mCD19/hCD20 chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated a 63.6% complete remission (CR) rate in a study that treated 11 patients with relapsed/refractory (r/r) B-cell nonHodgkin lymphoma (B-NHL).1 The data …